Ask AI
ProCE Banner Series

Beyond the Status Quo: Exploring the Future Impact of HBV Innovations

Join us for a live symposium to gain expert insight regarding limitations to current HBV therapy, emerging biomarkers, and therapies in the pipeline. Hear additional discussion about redefining goals of therapy with functional cure and learn about the clinical impact of emerging developments in care.

Unable to join us in Washington, DC? Register now for the online simulcast.

Presented for attendees of The Liver Meeting® 2025. This event/function is provided by Clinical Care Options and supported by Aligos Therapeutics. This is not an official event/function of the American Association for the Study of Liver Diseases.

You must be registered for the annual meeting to attend this session in-person.

  ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for physicians, nurses, and pharmacists, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients living with chronic hepatitis B.

All Events

Beyond the Status Quo: Exploring the Future Impact of HBV Innovations

Upcoming Events

November

10

2025

12:30 PM - 2:00 PM Eastern Time (ET)

In-personVirtual

Walter E. Washington Convention Center, 801 Allen Y. Lew Place NW, Washington, District of Columbia 20001

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge and competence regarding limitations of current HBV therapy and the clinical impact of emerging developments in care.

Target Audience
This activity is intended for physicians, nurses, and pharmacists, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients living with chronic hepatitis B.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Evaluate the limitations of current antiviral therapy for HBV
  • Outline the role of emerging biomarkers in evaluating disease status and treatment response for patients with HBV
  • Examine the role of emerging agents for chronic HBV suppression and their potential to improve patient outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-338-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

CCO 2022

Supporters

Supported by an educational grant from Aligos Therapeutics.

Aligos Therapeutics

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191